Supportive Care

Arrhythmia Risk Leads to Label Change for Zofran (07-9-2012)

Interim data from a recent clinical trial has indicated that a 32 mg single dose of Zofran® (ondansetron) may affect the electrical activity of the heart and could predispose patients to develop an abnormal heart rhythm. The U.S. Food and Drug Administration... Continue Reading

Social Support May Improve Breast Cancer Outcomes (01-26-2011)

Social well-being during the first year after a breast cancer diagnosis may have a beneficial effect on cancer outcomes. These results were published in the Journal of Clinical Oncology. A diagnosis of breast cancer often affects a woman’s quality of... Continue Reading

Xgeva Approved for Patients with Bone Metastases (11-30-2010)

Xgeva™ (denosumab) has been approved by the US Food and Drug Administration (FDA) for the prevention of bone complications such as fracture in patients with bone metastases from solid (not blood-related) cancers. It is not approved for patients with... Continue Reading